Captor Therapeutics is a Swiss-Polish drug discovery company listed on the Warsaw Stock Exchange. It is developing novel drugs in oncology and inflammation using Targeted Protein Degradation.
The most advanced drug is in IND-enabling studies and an authorisation for clinical trials is expected to be filed in 2023. The company entered into a collaboration with Ono Pharmaceutical at the end of 2022 in neurodegeneration and is interested in establishing additional partnerships around our pipeline and our targeted protein degradation discovery platform.
The most advanced drug is in IND-enabling studies and an authorisation for clinical trials is expected to be filed in 2023. The company entered into a collaboration with Ono Pharmaceutical at the end of 2022 in neurodegeneration and is interested in establishing additional partnerships around our pipeline and our targeted protein degradation discovery platform.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
